Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16834717 | 0.93 | MEN1 (0.43) | TSHRLTA4HNR5A1ALDH1A1TDP1 | |
| SCHEMBL16834549 | 0.93 | MEN1 (0.43) | TSHRLTA4HNR5A1ALDH1A1TDP1 | |
| SCHEMBL16834672 | 0.93 | MEN1 (0.43) | TSHRLTA4HNR5A1ALDH1A1TDP1 | |
| SCHEMBL28158410 | 0.91 | TSHR (0.40) | TSHRLTA4HNR5A1ALDH1A1CYP3A4 | |
| SCHEMBL17262613 | 0.89 | ALDH1A1 (0.37) | TSHRLTA4HALDH1A1TDP1NPC1 | |
| SCHEMBL19441385 | 0.87 | TSHR (0.38) | TSHRLTA4HNR5A1ALDH1A1CYP3A4 | |
| SCHEMBL13350505 | 0.85 | ALOX5 (0.41) | TSHRLTA4HNR5A1ALDH1A1CYP3A4 | |
| SCHEMBL17693427 | 0.85 | ALDH1A1 (0.42) | TSHRALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL17693435 | 0.84 | ALDH1A1 (0.36) | TSHRALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL3654147 | 0.84 | TSHR (0.36) | TSHRLTA4HNR5A1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2989094-A1 | CATALYTIC SYNTHESIS OF REDUCED FURAN DERIVATIVES | Archer Daniels Midland Company (US) | 2016-03-02 | — | — | EP | claimed |
| US-20160052902-A1 | CATALYTIC SYNTHESIS OF REDUCED FURAN DERIVATIVES | ARCHER DANIELS MIDLAND CO (US) | 2016-02-25 | — | — | US | claimed |
| WO-2014175989-A1 | CATALYTIC SYNTHESIS OF REDUCED FURAN DERIVATIVES | ARCHER DANIELS MIDLAND COMPANY (US) | 2014-10-30 | — | — | WO | claimed |
| CN-105801528-B | With metal catalyst reduction HMF ether | 阿彻丹尼尔斯米德兰德公司 | 2019-06-21 | — | — | CN | disclosed |
| US-9783516-B2 | Reduction of HMF ethers with metal catalyst | ARCHER DANIELS MIDLAND CO. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783516-B2 | Reduction of HMF ethers with metal catalyst | ARCHER DANIELS MIDLAND CO. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3142966-A1 | HYDROGENATION OF OXYGENATED MOLECULES FROM BIOMASS REFINING | Virdia, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| CN-103626639-B | With metal catalyst reduction HMF ether | 阿彻丹尼尔斯米德兰德公司 | 2016-12-07 | — | — | CN | disclosed |
| US-20160297788-A1 | REDUCTION OF HMF ETHERS WITH METAL CATALYST | ARCHER DANIELS MIDLAND CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297788-A1 | REDUCTION OF HMF ETHERS WITH METAL CATALYST | ARCHER DANIELS MIDLAND CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-9422258-B2 | Reduction of HMF ethers with metal catalyst | ARCHER DANIELS MIDLAND COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| CN-103626639-A | Reduction of HMF ethers with metal catalyst | ARCHER DANIELS MIDLAND CO | 2014-03-12 | — | — | CN | disclosed |
| US-20120261618-A1 | REDUCTION OF HMF ETHERS WITH METAL CATALYST | ARCHER DANIELS MIDLAND COMPANY (US) | 2012-10-18 | — | — | US | disclosed |
| CN-102177146-A | Reduction of HMF ethers with metal catalysts | ARCHER DANIELS MIDLAND CO | 2011-09-07 | — | — | CN | disclosed |
| EP-2350035-A2 | REDUCTION OF HMF ETHERS WITH METAL CATALYST | Archer Daniels Midland Company (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010062689-A2 | REDUCTION OF HMF ETHERS WITH METAL CATALYST | ARCHER DANIELS MIDLAND COMPANY (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062689-A2 | REDUCTION OF HMF ETHERS WITH METAL CATALYST | ARCHER DANIELS MIDLAND COMPANY (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20090018300-A1 | MONOMERS AND POLYMERS FROM BIODERIVED CARBON | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018300-A1 | MONOMERS AND POLYMERS FROM BIODERIVED CARBON | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018300-A1 | MONOMERS AND POLYMERS FROM BIODERIVED CARBON | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297788-A1 | REDUCTION OF HMF ETHERS WITH METAL CATALYST | PHF2, ZRANB2, TERF2 | TSHR 2837/4885LTA4H 3370/4885NR5A1 1295/4885 |
| US-20120261618-A1 | REDUCTION OF HMF ETHERS WITH METAL CATALYST | PHF2, ZRANB2, TERF2 | TSHR 2753/4885LTA4H 3405/4885NR5A1 1214/4885 |
| US-20160052902-A1 | CATALYTIC SYNTHESIS OF REDUCED FURAN DERIVATIVES | ADH5, FASN, ADH1C | TSHR 3989/4885LTA4H 462/4885NR5A1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.